

# MarÃ-a C LondoÃ±o

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5522162/publications.pdf>

Version: 2024-02-01

94  
papers

3,914  
citations

182225

30  
h-index

139680

61  
g-index

97  
all docs

97  
docs citations

97  
times ranked

4867  
citing authors

#	ARTICLE	IF	CITATIONS
1	Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 732-740.	2.4	19
2	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , 2022, 75, 13-27.	3.6	16
3	Noninvasive Prediction of Outcomes in Autoimmune Hepatitis-Related Cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 1392-1402.	2.0	5
4	Relevancia de la Cartas Científicas. <i>Gastroenterología Y Hepatología</i> , 2022, , .	0.2	0
5	The optimal immunosuppression management to prevent early rejection after liver transplantation: A systematic review of the literature and expert panel recommendations. <i>Clinical Transplantation</i> , 2022, 36, e14614.	0.8	5
6	Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency-associated hypertransaminasemia. <i>Hepatology</i> , 2022, 76, 1259-1274.	3.6	8
7	Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 131-143.	1.9	9
8	Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome. <i>Hepatology</i> , 2022, 76, 1576-1586.	3.6	58
9	Tacrolimus as an Effective and Durable Second-Line Treatment for Chronic Autoimmune Hepatitis: A Multicentric Study. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2826-2832.	1.1	6
10	Impact of donor extracellular vesicle release on recipient cell "cross-dressing" following clinical liver and kidney transplantation. <i>American Journal of Transplantation</i> , 2021, 21, 2387-2398.	2.6	25
11	On the impact of hepatitis C virus and heterologous immunity on alloimmune responses following liver transplantation. <i>American Journal of Transplantation</i> , 2021, 21, 247-257.	2.6	8
12	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. <i>Journal of Autoimmunity</i> , 2021, 117, 102580.	3.0	23
13	Another case of autoimmune hepatitis after SARS-CoV-2 vaccination " still casualty?. <i>Journal of Hepatology</i> , 2021, 75, 1248-1249.	1.8	72
14	Budesonide in the first line treatment of patients with autoimmune hepatitis. <i>Gastroenterología Y Hepatología</i> , 2021, , .	0.2	0
15	Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV cirrhotic patients. <i>Journal of Gastroenterology</i> , 2020, 55, 205-216.	2.3	19
16	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020, 174, 104694.	1.9	39
17	Higher seroprevalence of hepatitis E virus in autoimmune hepatitis: Role of false-positive antibodies. <i>Liver International</i> , 2020, 40, 558-564.	1.9	10
18	Improvement of sexuality after hepatitis C cure with direct acting antivirals. <i>Liver International</i> , 2020, 40, 2972-2977.	1.9	3

#	ARTICLE	IF	CITATIONS
19	Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025. <i>Journal of Hepatology</i> , 2020, 73, 1360-1367.	1.8	12
20	Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors. <i>Cancers</i> , 2020, 12, 3446.	1.7	19
21	Chronic genotype 1 hepatitis C along with cirrhosis drives a persistent imprint in virus-specific CD8 + T cells after direct-acting antiviral therapies. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1408-1418.	1.0	4
22	Predictive factors of response to corticosteroid therapy in acute severe autoimmune hepatitis: a national multicentric study. <i>Journal of Hepatology</i> , 2020, 73, S468-S469.	1.8	0
23	Cirrhosis Hampers Early and Rapid Normalization of Natural Killer Cell Phenotype and Function in Hepatitis C Patients Undergoing Interferon-Free Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 129.	2.2	7
24	Ductular reaction and hepatocyte ballooning identify patients with fibrosing cholestatic hepatitis after liver transplantation. <i>Gastroenterology &amp; Hepatology (English Edition)</i> , 2020, 43, 14-21.	0.0	0
25	Ductular reaction and hepatocyte ballooning identify patients with fibrosing cholestatic hepatitis after liver transplantation. <i>Gastroenterology &amp; Hepatology</i> , 2020, 43, 14-21.	0.2	2
26	FRI-039-Autoimmune hepatitis-related cirrhosis: The importance of treatment response and the utility of Baveno VI criteria. <i>Journal of Hepatology</i> , 2019, 70, e401.	1.8	0
27	Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice “Vie-KinD study. <i>PLoS ONE</i> , 2019, 14, e0221567.	1.1	7
28	Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia. <i>Gastroenterology &amp; Hepatology</i> , 2019, 42, 164-170.	0.2	3
29	Presentation and Outcomes of Pregnancy in Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2819-2821.	2.4	24
30	Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia. <i>Gastroenterology &amp; Hepatology (English Edition)</i> , 2019, 42, 164-170.	0.0	0
31	Calidad de vida en los pacientes con hepatitis C. Importancia del tratamiento. <i>Gastroenterology &amp; Hepatology</i> , 2019, 42, 20-25.	0.2	1
32	Contributing awareness of autoimmune hepatitis in HIV patients. <i>Aids</i> , 2019, 33, 2103-2105.	1.0	0
33	Simplified follow-up of patients with mild chronic hepatitis C in areas with limited access to antiviral therapy. <i>Digestive and Liver Disease</i> , 2019, 51, 875-881.	0.4	0
34	Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis. <i>Liver International</i> , 2019, 39, 826-834.	1.9	15
35	The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition. <i>Journal of Hepatology</i> , 2018, 69, 11-17.	1.8	80
36	Anti-viral therapy can be delayed or avoided in a significant proportion of HBsAg-negative Caucasian patients in the Grey Zone. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1397-1408.	1.9	46

#	ARTICLE	IF	CITATIONS
37	Reply to: "Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations", Journal of Hepatology, 2018, 68, 627-628.	1.8	0
38	Molecular profiling of subclinical inflammatory lesions in long-term surviving adult liver transplant recipients. Journal of Hepatology, 2018, 69, 626-634.	1.8	46
39	Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney. Journal of Nephrology, 2018, 31, 1-13.	0.9	11
40	Potential drug-drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir ± DASABUVIR ± ribavirin in clinical practice. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1100-1107.	1.4	5
41	Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. Hepatology, 2018, 67, 1683-1694.	3.6	114
42	Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study. American Journal of Transplantation, 2018, 18, 2513-2522.	2.6	32
43	Long-term impact of HCV eradication after all-oral therapy in patients with clinical significant portal hypertension. Journal of Hepatology, 2018, 68, S84.	1.8	1
44	Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure. Gastroenterology, 2018, 155, 311-315.e6.	0.6	73
45	Long-term subclinical inflammatory lesions in liver transplant recipients. Journal of Hepatology, 2018, 68, S379-S380.	1.8	1
46	Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals. Journal of Viral Hepatitis, 2018, 25, 1515-1525.	1.0	10
47	Hepatitis C viremia as a risk factor for opportunistic infections in kidney transplant recipients. Clinical Transplantation, 2018, 32, e13382.	0.8	4
48	Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen. Alimentary Pharmacology and Therapeutics, 2017, 45, 1156-1161.	1.9	47
49	Successful Continuation of HCV Treatment After Liver Transplantation. Transplantation, 2017, 101, 1009-1012.	0.5	6
50	Treating Hepatitis C in Patients with Renal Failure. Digestive Diseases, 2017, 35, 339-346.	0.8	14
51	Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study. Transplant International, 2017, 30, 1041-1050.	0.8	6
52	Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 585-594.	3.7	71
53	Letter: hepatitis B reactivation in patients with chronic hepatitis C during direct-acting antiviral therapy" authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 1559-1560.	1.9	2
54	Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. Journal of Hepatology, 2017, 66, 718-723.	1.8	90

#	ARTICLE	IF	CITATIONS
55	Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. <i>Journal of Hepatology</i> , 2017, 67, 1168-1176.	1.8	96
56	Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. <i>Gastroenterology</i> , 2017, 153, 1273-1283.e1.	0.6	210
57	Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 575-583.e1.	2.4	99
58	Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir-Containing Hepatitis C Virus Treatment. <i>Annals of Hepatology</i> , 2017, 16, 312-317.	0.6	1
59	Foamy Histiocyte-Like Hepatocellular Carcinoma (HCC): A New Variant of HCC?. <i>Annals of Hepatology</i> , 2017, 16, 304-307.	0.6	7
60	Hepatitis C Virus RNA Persists in Liver Explants of Most Patients Awaiting Liver Transplantation Treated With an Interferon-Free Regimen. <i>Gastroenterology</i> , 2016, 151, 633-636.e3.	0.6	19
61	Hepatic Infiltrates in Operational Tolerant Patients After Liver Transplantation Show Enrichment of Regulatory T Cells Before Proinflammatory Genes Are Downregulated. <i>American Journal of Transplantation</i> , 2016, 16, 1285-1293.	2.6	63
62	Targeting hepatitis C after liver transplantation. <i>Liver Transplantation</i> , 2016, 22, 9-11.	1.3	1
63	Reactivation of Herpesvirus in Patients With Hepatitis C Treated With Direct-Acting Antiviral Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1662-1666.e1.	2.4	38
64	IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3195-3201.	1.3	11
65	Treatment of hepatitis C before and after liver transplantation. <i>Gastroenterology and Hepatology (English Edition)</i> , 2016, 39, 344-351.	0.0	0
66	Peripheral phenotype and gene expression profiles of combined liver-kidney transplant patients. <i>Liver International</i> , 2016, 36, 401-409.	1.9	7
67	Molecular Characterization of Acute Cellular Rejection Occurring During Intentional Immunosuppression Withdrawal in Liver Transplantation. <i>American Journal of Transplantation</i> , 2016, 16, 484-496.	2.6	38
68	Predicting the development of liver cirrhosis by simple modelling in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 364-374.	1.9	14
69	Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon. <i>PLoS ONE</i> , 2016, 11, e0166631.	1.1	5
70	Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV-decompensated cirrhosis: viral eradication and removal from the liver transplant waiting list. <i>Transplant International</i> , 2015, 28, 1345-1349.	0.8	15
71	Hepatitis C treatment for patients post liver transplant. <i>Current Opinion in Organ Transplantation</i> , 2015, 20, 251-258.	0.8	5
72	Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2015, 21, 5421.	1.4	7

#	ARTICLE	IF	CITATIONS
73	The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis. <i>Journal of Hepatology</i> , 2015, 62, 311-316.	1.8	12
74	Clinical trial watch: Reports from the AASLD Liver Meeting®, Boston, November 2014. <i>Journal of Hepatology</i> , 2015, 62, 1196-1203.	1.8	22
75	HEV infection in two referral centers in Spain; epidemiology and clinical outcomes. <i>Journal of Clinical Virology</i> , 2015, 63, 76-80.	1.6	21
76	Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. <i>Hepatology</i> , 2015, 61, 1485-1494.	3.6	206
77	Sustained Virological Response and Hepatitis C-Related Cirrhosis: a World of Opportunities. <i>Current Hepatology Reports</i> , 2015, 14, 32-39.	0.4	0
78	Grazoprevir plus elbasvir in treatment-naïve and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. <i>Lancet, The</i> , 2015, 386, 1537-1545.	6.3	625
79	Interferon-Free Regimens in the Liver-Transplant Setting. <i>Seminars in Liver Disease</i> , 2014, 34, 058-071.	1.8	34
80	HCV-Induced Immune Responses Influence the Development of Operational Tolerance After Liver Transplantation in Humans. <i>Science Translational Medicine</i> , 2014, 6, 242ra81.	5.8	74
81	Liver Stiffness 1 Year After Transplantation Predicts Clinical Outcomes in Patients With Recurrent Hepatitis C. <i>American Journal of Transplantation</i> , 2014, 14, 375-383.	2.6	53
82	P1135 ADDITION OF TELAPREVIR OR BOCEPREVIR TO PEG-RIB THERAPY INCREASES THE RISK OF INFECTIONS IN PATIENTS WITH HEPATITIS C-RELATED CIRRHOSIS (HCV-CH): A COMPARATIVE STUDY. <i>Journal of Hepatology</i> , 2014, 60, S460.	1.8	1
83	Immunosuppression minimization vs. complete drug withdrawal in liver transplantation. <i>Journal of Hepatology</i> , 2013, 59, 872-879.	1.8	97
84	Interferon free regimens for the "difficult-to-treat": Are we there?. <i>Journal of Hepatology</i> , 2013, 58, 643-645.	1.8	6
85	Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. <i>Hepatology</i> , 2013, 58, 1824-1835.	3.6	269
86	Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors. <i>Current Opinion in Organ Transplantation</i> , 2013, 18, 271-278.	0.8	5
87	A Need for Biomarkers of Operational Tolerance in Liver and Kidney Transplantation. <i>American Journal of Transplantation</i> , 2012, 12, 1370-1377.	2.6	51
88	Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. <i>Journal of Clinical Investigation</i> , 2012, 122, 368-382.	3.9	183
89	Minimization of immunosuppression in adult liver transplantation: new strategies and tools. <i>Current Opinion in Organ Transplantation</i> , 2010, 15, 685-690.	0.8	11
90	Management of biliary complications after orthotopic liver transplantation: The role of endoscopy. <i>World Journal of Gastroenterology</i> , 2008, 14, 493.	1.4	81

#	ARTICLE	IF	CITATIONS
91	MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. <i>Gut</i> , 2007, 56, 1283-1290.	6.1	180
92	Hyponatremia Impairs Early Posttransplantation Outcome in Patients With Cirrhosis Undergoing Liver Transplantation. <i>Gastroenterology</i> , 2006, 130, 1135-1143.	0.6	179
93	Sequential Determination of Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid in Liver Transplant Patients Treated with Mycophenolate Mofetil. <i>Transplantation</i> , 2006, 81, 541-546.	0.5	55
94	Applicability of adult-to-adult living donor liver transplantation. <i>Journal of Hepatology</i> , 2005, 43, 104-109.	1.8	30